AU2019262200A1 - Methods and compositions for killing a target bacterium - Google Patents

Methods and compositions for killing a target bacterium Download PDF

Info

Publication number
AU2019262200A1
AU2019262200A1 AU2019262200A AU2019262200A AU2019262200A1 AU 2019262200 A1 AU2019262200 A1 AU 2019262200A1 AU 2019262200 A AU2019262200 A AU 2019262200A AU 2019262200 A AU2019262200 A AU 2019262200A AU 2019262200 A1 AU2019262200 A1 AU 2019262200A1
Authority
AU
Australia
Prior art keywords
bacteriophage
crispr
cas system
target
bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019262200A
Other languages
English (en)
Inventor
Paul M. GAROFOLO
David G. Ousterout
Kurt SELLE
Hannah Hewitt TUSON
Sandi WONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Locus Biosciences Inc
Original Assignee
Locus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locus Biosciences Inc filed Critical Locus Biosciences Inc
Publication of AU2019262200A1 publication Critical patent/AU2019262200A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2019262200A 2018-05-04 2019-05-03 Methods and compositions for killing a target bacterium Abandoned AU2019262200A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862667400P 2018-05-04 2018-05-04
US62/667,400 2018-05-04
US201862743740P 2018-10-10 2018-10-10
US62/743,740 2018-10-10
US201962818066P 2019-03-13 2019-03-13
US62/818,066 2019-03-13
PCT/US2019/030695 WO2019213592A1 (en) 2018-05-04 2019-05-03 Methods and compositions for killing a target bacterium

Publications (1)

Publication Number Publication Date
AU2019262200A1 true AU2019262200A1 (en) 2020-12-17

Family

ID=68386731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019262200A Abandoned AU2019262200A1 (en) 2018-05-04 2019-05-03 Methods and compositions for killing a target bacterium

Country Status (10)

Country Link
US (5) US20200354690A1 (https=)
EP (1) EP3788152A4 (https=)
JP (1) JP2021522857A (https=)
KR (1) KR20210018273A (https=)
CN (1) CN112424363A (https=)
AU (1) AU2019262200A1 (https=)
CA (1) CA3099316A1 (https=)
TW (1) TW202014519A (https=)
UY (1) UY38215A (https=)
WO (1) WO2019213592A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3711488A1 (en) 2015-05-06 2020-09-23 Snipr Technologies Limited Altering microbial populations & modifying microbiota
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
FR3096373B1 (fr) * 2019-05-24 2024-09-13 Ifp Energies Now Outil genetique optimisé pour modifier les bacteries
US20220265766A1 (en) * 2019-07-30 2022-08-25 The Regents Of The University Of California Antimicrobial therapy through the combination of pore-forming agents and histones
WO2021092254A1 (en) * 2019-11-06 2021-05-14 Locus Biosciences, Inc. Phage compositions comprising crispr-cas systems and methods of use thereof
US20230002761A1 (en) * 2019-11-19 2023-01-05 Benson Hill, Inc. Anti-bacterial crispr compositions and methods
CA3171941A1 (en) * 2020-03-16 2021-09-23 Joseph E. Peters Compositions and methods comprising improved guide rnas
WO2021195594A1 (en) * 2020-03-26 2021-09-30 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Compositions and methods for treating or ameliorating infections
WO2021231689A1 (en) * 2020-05-14 2021-11-18 Chan Zuckerberg Biohub, Inc. Phage-mediated delivery of genes to gut microbiome
GB202007943D0 (en) * 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
CA3197277A1 (en) * 2020-11-05 2022-05-12 Paul GAROFOLO Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof
US20240011041A1 (en) * 2020-11-05 2024-01-11 Locus Biosciences, Inc. Phage compositions for pseudomonas comprising crispr-cas systems and methods of use thereof
SK289101B6 (sk) * 2020-12-17 2023-08-09 Ústav molekulárnej biológie Slovenskej akadémie vied, verejná výskumná inštitúcia Antimikrobiálny proteín, antimikrobiálny rekombinantný proteín s lytickými vlastnosťami, expresný vektor, spôsob ich prípravy a použitie
WO2022235816A2 (en) * 2021-05-05 2022-11-10 Locus Biosciences, Inc. Bacteriophage comprising type i crispr-cas systems
WO2022235799A2 (en) * 2021-05-05 2022-11-10 Locus Biosciences, Inc. Phage compositions for staphylococcus comprising crispr-cas systems and methods of use thereof
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
EP4604969A1 (en) * 2022-10-17 2025-08-27 Locus Biosciences, Inc. Staphylococcus phage compositions and cocktails thereof
CN117210413B (zh) * 2023-08-04 2026-04-21 湖北文理学院 纹带棒状杆菌噬菌体及其应用
WO2025109112A1 (en) * 2023-11-22 2025-05-30 Centre National De La Recherche Scientifique Engineered phagemids and methods for antibacterial peptide delivery against bacterial pathogens in particular clostridioides difficile
US12274722B1 (en) * 2024-04-24 2025-04-15 Phage Technology Center Gmbh Antibiotic free treatment of mastitis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2341149T3 (en) * 2005-08-26 2017-02-27 Dupont Nutrition Biosci Aps Use of CRISPR-associated genes (Cas)
CN101688241B (zh) * 2007-03-02 2015-01-21 杜邦营养生物科学有限公司 具有改善的噬菌体抗性的培养物
CN106536739B (zh) * 2014-04-14 2021-08-03 内梅西斯生物有限公司 治疗剂
HRP20200529T1 (hr) * 2014-06-06 2020-09-04 Regeneron Pharmaceuticals, Inc. Postupci i pripravci za modificiranje ciljnog lokusa
CN107208070B (zh) * 2014-11-26 2021-09-07 技术创新动力基金（以色列）有限合伙公司 细菌基因的靶向消除
EP3711488A1 (en) * 2015-05-06 2020-09-23 Snipr Technologies Limited Altering microbial populations & modifying microbiota
WO2016205276A1 (en) * 2015-06-15 2016-12-22 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
EP4089175A1 (en) * 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US11311582B2 (en) * 2015-11-19 2022-04-26 Locus Biosciences, Inc. Bacteriophage compositions and methods of use thereof
US11542466B2 (en) * 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
WO2017223101A1 (en) * 2016-06-22 2017-12-28 The United States Of America As Represented By The Secretary Of The Navy Bacteriophage compositions and methods of selection of components against specific bacteria
US11672839B2 (en) * 2016-12-05 2023-06-13 Technechnophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
GB201710126D0 (en) * 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
KR20210006344A (ko) 2018-03-25 2021-01-18 에스엔아이피알 바이옴 에이피에스. 미생물 감염의 치료 및 예방

Also Published As

Publication number Publication date
KR20210018273A (ko) 2021-02-17
US20220380736A1 (en) 2022-12-01
EP3788152A1 (en) 2021-03-10
EP3788152A4 (en) 2022-03-09
JP2021522857A (ja) 2021-09-02
CN112424363A (zh) 2021-02-26
US20220002681A1 (en) 2022-01-06
US20220387531A1 (en) 2022-12-08
WO2019213592A1 (en) 2019-11-07
UY38215A (es) 2019-11-29
US20200354690A1 (en) 2020-11-12
US20230038106A1 (en) 2023-02-09
TW202014519A (zh) 2020-04-16
CA3099316A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
US20230038106A1 (en) Methods and compositions for killing a target bacterium
US20220370526A1 (en) Phage compositions comprising crispr-cas systems and methods of use thereof
US20220389392A1 (en) Crispr cas systems and lysogeny modules
US20220411782A1 (en) Phage compositions comprising crispr-cas systems and methods of use thereof
US20240011041A1 (en) Phage compositions for pseudomonas comprising crispr-cas systems and methods of use thereof
US20210161150A1 (en) Methods and compositions for killing a target bacterium
WO2022235816A2 (en) Bacteriophage comprising type i crispr-cas systems
US20240067935A1 (en) Altering the normal balance of microbial populations
WO2022235799A2 (en) Phage compositions for staphylococcus comprising crispr-cas systems and methods of use thereof
US20250345378A1 (en) Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof
US20260124259A1 (en) Staphylococcus phage compositions and cocktails thereof
US20230398161A1 (en) Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof
WO2024086532A1 (en) Staphylococcus phage compositions and cocktails thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period